Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. Yes, it may be holiday time for many, but the world continues to spin for the rest of us. So fire up your coffee kettles and prepare for another round of meetings, deadlines, text messages, conference calls, encrypted chatter, and whatever else helps you move down the assembly line. Meanwhile, please enjoy the items of interest we have gathered. Hope your day is smashing and, as always, do keep in touch. We appreciate the missives, tips and suggestions. …

A historic clinical trial has shown that two therapies made from Ebola antibodies appear to be improving survival rates among people who receive them, STAT reports. The announcement marks the first time a clinical trial has successfully shown that an Ebola therapy improves survival in people who have been infected. Only limited and preliminary data are available at this point, but the therapies showed mortality rates ranging from 29% to 53%.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.